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Paul R. Lockman, PhD, BSN
School of Pharmacy, West Virginia University, Morgantown, West Virginia
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Objective. To develop an effective method in teaching pharmacogenomics as a part of a new course,
Biopharmaceutics and Pharmacogenomics.
Methods. Teaching effectiveness was measured by quizzes, retrospective pre- and post-surveys, team
activities, and journal reflections. Four team activities were included in the course: genomic disease,
patient case, genetic counselor and a debate about personalized medicine. Outcomes and course impact
were evaluated at the end of the course. The evaluation methods included the assessment of knowledge,
students’ perceptions regarding the utility of team activities, the impact of the course on students’
confidence to discuss pharmacogenomics with health care providers or patients, and long-term knowledge retention, measured in the following P2 semester.
Results. Seventy-six students were enrolled in the course. Multiple assessments during the course
demonstrated that students’ knowledge of pharmacogenomics improved. The team activities had
a positive impact on student learning, and the course improved their confidence level to discuss
pharmacogenomics with another health care provider or a patient. While 86% of the students considered themselves “unconfident,” “somewhat unconfident” or “neither confident nor unconfident” at the
beginning of the course, 91% reported being “confident” or “somewhat confident” by the end of the
course. This increase in confidence was statistically significant. Furthermore, students showed knowledge retention six months after taking the course.
Conclusion. Implementation of a new course in pharmacogenomics was effective and well received by
the students. It also prepared students for system-based therapeutics courses later in the curriculum.
Keywords: pharmacogenomics, pharmacogenetics, critical thinking, concepts integration, new course

interpretation, communication, and professionalism.3,4
These core competencies have been endorsed by major
health organizations, including the National Coalition for
Health Professional Education in Genetics (NCHPEG),4
the International Society of Pharmacogenomics,5 the Accreditation Council for Pharmacy Education (ACPE),2
American College of Clinical Pharmacy (ACCP),7 the
American College of Clinical Pharmacy (ACCP) Educational Affairs Committee, the American Society of
Health-System Pharmacists (ASHP),8 and the NIHfunded Genetic/Genomics Competency Center (G2C2).2
Following these recommendations, multiple approaches describing the incorporation of pharmacogenomics in the education of health care providers have been published.9–11 A
pharmacist’s responsibilities are to educate patients about
pharmacogenomic principles and to advocate the rational
and routine use of pharmacogenomic testing when indicated.8
These recommendations can be assisted by the advances in new technologies and direct-to-consumer testing offered by many companies. However, social media

INTRODUCTION
Although the idea of individualized response to treatments was observed by Lucretius in 50 BC defending that
“What is food to one man, is bitter poison to others,” it
wasn’t until 1950 when the concepts of “pharmacogenetics” and “pharmacogenomics” were introduced.1 With
the new Accreditation Council for Pharmacy Education
(ACPE) Standards, pharmacy students should be prepared to understand and apply pharmacogenomics concepts to patient care.2
The National Human Genome Research Institute
(NHGRI) of the National Institutes of Health identified five
core competencies with respect to pharmacogenomic educational needs for pharmacists: terminology, knowledge,
Corresponding Author: Marina Gálvez-Peralta, Department
of Pharmaceutical Sciences, School of Pharmacy, 1 Medical
Center Dr., West Virginia University, Morgantown, WV
26506. Tel: 304-293-1480. E-mail: magalvezperalta@hsc.
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convey the somewhat overly optimistic promises that all
diseases will become treatable after the completion of the
genomic project.12 Therefore, pharmacists must become
leaders and key professionals who provide valid information about pharmacogenomics to patients and other health
care providers.
These scientific and social factors were considered
when the new course, “Biopharmaceutics and Pharmacogenomics,” was designed. That is why several group activities were included, with the objective of enhancing
students’ critical thinking and knowledge. This course
is offered during the spring semester of the first year
(P1) of the 4-year PharmD professional program at the
School of Pharmacy at West Virginia University. At WVU,
students are accepted after a minimum of two years of prepharmacy education.
The PharmD program at the WVU School of Pharmacy underwent a curricular change in 2015 with the integration of basic and clinical sciences within courses.
While in the traditional curriculum, pharmacogenomics
was taught in the P3 fall course as part of the course
“Pharmacokinetics and Pharmacogenomics,” in the new
curriculum, pharmacogenomics was moved to the P1
spring semester. The ultimate goals of this change were
two-fold: first, to provide a basis to understand and to
interpret pharmacogenomics information and, second,
to be able to apply pharmacogenetic principles in future
system-based therapeutic courses offered during P2 and
P3 years. With this new model, students would have already acquired a foundation in pharmacokinetics, biopharmaceutics, biotechnology, and biochemical pharmacology
prior to or during the same semester that the pharmacogenomics module was offered. The pharmacogenomics section of the course was designed with formal lectures, class
discussions, homework assignments, journal reflections,
and team activities that included, among others, a debate
about personalized medicine and a genetic counselor guest
speaker (further details in the method section). The authors
of this study hypothesized that the introduction of pharmacogenomics early in the students’ curriculum and the use of
these specific active learning activities would set the foundations to apply pharmacogenetics concepts in their pharmacy practice.

instructor. Sessions were divided between lecture time
and team activities. The focus of the latter was to enhance
the learning and applicability of pharmacogenomics to
pharmacy practice.
Student learning was assessed with quizzes, retrospective pre- and post-surveys, team activities, and journal
reflections (this last one was not graded and voluntary).
Outcomes and course impact were measured from a survey
at the end of the course.
Four team activities were offered in the pharmacogenomics section of the course. A summary of their description with the objectives and NHGRI and Center for
the Advancement of Pharmacy Education (CAPE) competencies are summarized in Table 1.
The first activity required each team to write a fourpage long paper describing a Mendelian disease of their
choice, type of inheritance, variations that could cause
disease severity, frequency of distribution among different ethnicities or races, changes in the diagnosis and treatment of the disease (traditional vs genomic era), and the
role of the pharmacist in helping patients understand the
disease. The objective of this activity was to familiarize
students with different databases, pedigrees, and genetic
terminology. This activity covered terminology, knowledge, interpretation, and professionalism as the core genomic educational needs recommended by the NHGRI
and pharmacists organizations.3 The paper was evaluated
for content and professionalism in its format. The following resources were suggested to students as an aid for the
assignment: Genetics Home Reference, Genes and Disease, Medline Plus, Genetic Testing Registry, Single Nucleotide Polymorphism, and Clinical Trials.gov.
The second activity was a short verbal presentation on
a drug of their choice addressing the gene and variant allele
affected, penetrance and expressivity, phenotype, pharmacokinetic and/or pharmacodynamics consequences, therapeutic recommendations such as dose adjustment, change of
medication, need for screening prior to prescribing the therapy, recommendation for monitoring drug levels, and level
of evidence indicated by the Clinical Pharmacogenetics
Implementation Consortium (CPIC), using PharmGKB
and FDA package insert recommendations. The learning
objectives for this activity were to familiarize students
with the PharmGKB website, identify levels of evidence,
determine when dosing guidelines or other recommendations are being approved, and counsel for specific drugs
linked to genotypes. This activity would train students in
pharmacogenetics/pharmacogenomics terminology, knowledge, interpretation, communication, and professionalism3
for their future careers in pharmacy.
The third activity consisted of a genetic counseling
session that included obtaining a firsthand input from

METHODS
The Biopharmaceutics and Pharmacogenomics
course was first implemented in the spring of 2016 as
a four-credit course. One hour per week was dedicated
for a team activity or a quiz, while the other three sessions
were for lectures. The sessions that discussed pharmacogenomics were offered in the second half of the semester,
with a total of 29 sessions, and conducted mostly by one
955
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Table 1. Comparison of Activities, Objectives, Educational Genomic Core Need Addressed, and Educational Outcomes (CAPE)
Team
Activity
#

Type of Activity

Educational
Genomic Core
Need Addressed

Objectives

Educational Outcomes
(CAPE)

1

Paper exploring
Mendelian Disease

Familiarization with databases,
pedigrees and genetic
terminology.

Terminology
Knowledge
Interpretation
Professionalism

Knowledge (1)

2

Verbal presentation on
pharmacogenomics

Familiarization with PharmGKB,
levels of evidence, dosing
guidelines/recommendations
and counseling.

Terminology
Knowledge
Interpretation
Communication
Professionalism

Knowledge (1), Improving
communication (3),
Empathy and
self-awareness (4)

3

Genetic counseling

Role playing

Knowledge
Interpretation
Communication
Professionalism

Knowledge (1), Improving
communication (3),
Self-awareness (4)

4

Class debate about
personalized medicine
and genetic
sequencing

Comparison of information posted
on social media with scientific
data. Ethics, law and regulations
of genetic information. Prepare
students to answer real patients’
questions and information
posted on social media.

Terminology
Knowledge
Interpretation
Communication
Professionalism

Knowledge (1), Improving
communication (3),
Cultural sensitivity (3),
Empathy and
self-awareness (4)

a genetic counselor about genotoxicity and a role-play
session. In the latter session, students role-played as pharmacists and enacted how they would counsel if they had
the Mendelian disease that they worked on during the first
assignment, or if the patient is taking the medication that
was investigated in the second assignment.
The fourth activity was a class debate on personalized medicine. This activity took place after the lectures
on legal and ethical components of pharmacogenomics.
The debate was divided in two sessions on consecutive
days. At the beginning of the pharmacogenomic sessions,
teams were randomly assigned to be “for” or “against”
personalized medicine and given enough time to compile
and contrast information by the end of the semester. During the first session, the team leaders justified the reasoning behind their assigned point of view. During the second
session, the instructor (debate facilitator) brought up the
most common topics mentioned by the team leaders, and
they were discussed by all the students. In addition, students completed a survey to measure their personal inclination toward the topic before, during, and after the
debate to obtain their perceptions about personalized
medicine and genetic sequencing. The learning objective
for this activity was to prepare student pharmacists to face

real patients’ questions, concerns, and information posted
in social media, with the ultimate goal of educating patients, and to become an advocate for the rational and
routine use of pharmacogenomic testing in appropriate
circumstances.3,8
Students were asked to sign up for a 6-8 member team
with classmates of their choice. These teams were maintained throughout the entire pharmacogenomics section of
the course. Team members chose a leader for each group
activity. The aim of including a leader was to enhance
student professionalism and leadership skills. Students
peer-reviewed by providing feedback on accountability,
participation, communication, responsibility, identification
of skills, and cooperation. This feedback was shared anonymously with individual students for personal development.
A voluntary and anonymous survey was offered to
students at the end of the course to evaluate the utility of
having group learning activities and the potential benefits
of the individual team activities. In addition to the team
activities, students were engaged in other activities during
lecture times, such as real-time audience questions using
the SOLE (Study Observe Learn Engage West Virginia
University Health Science portal) surveys to monitor
and assess in real-time their understanding of the topic
956
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discussed that day as well as clinical cases prior to the
introduction of some concepts.
The course impact on student confidence in pharmacogenomics was measured by asking them anonymously
for their perception regarding the level of confidence in
pharmacogenomics counseling or discussing this topic
with other health care providers. The retrospective survey
included questions measuring student confidence before
and after taking the course, with both types of questions
given at the end of the course. This allowed the study
authors to compare anonymously retrospective pre- and
post-answers for individual students, and to ensure an
identical level of participation. The results of the preand post-retrospective survey were evaluated with Chisquare test using Prism 5.0 (GraphPad Software Inc., La
Jolla, CA). This study was approved by West Virginia
University Institutional Review Board as exempt.
Long-term knowledge retention was tested 6 months
after the pharmacogenomics course was finalized, during
P2 fall semester in System Based Therapeutic Courses
(SBT), without early notice to students. Several nongraded questions were part of one of the sessions, and
the responses helped the instructor to assess the level of
students’ pharmacogenomics knowledge retention and
understanding prior to introducing specific clinical scenarios. The questions referred to basic concepts or drugs
mentioned in the P1 Biopharmaceutics and Pharmacogenomics course and were answered anonymously with no
grade associated to it. In addition, new pharmacogenomics questions were asked in some examinations in systembased therapeutic courses. These questions involved more
complex concepts, clinical scenarios and exceptions, and
were used to assess the utility of introducing a pharmacogenomics module in the first year, as well as the retention
of basic concepts.

Table 2. Percentage of Questions Answered Correctly Based
on Bloom’s Level in Different Quizzes and Final Examination
Bloom’s Level
Knowledge
Comprehension
Analysis
Application
Synthesize/
Evaluate/Create

Number of % of Questions Answered
Questions
Correctly, Mean (SD)
19
72
40
45
71

91
89
80
83
85

(8)
(10)
(11)
(14)
(8)

the class answered the questionnaire. Ninety-two percent
of the students who answered the questionnaire found the
incorporation of active learning activities to be very useful or somewhat useful, and would recommend the activities to other students. Moreover, 95% of students agreed
or strongly agreed that the activities helped them to acquire new knowledge, while 4% were neutral, and 92%
were satisfied with those activities. In addition, 92% of
students agreed or strongly agreed that the learning environment was conductive.
The activity considered to be the most useful (very
useful or somewhat useful) by 94% of students was the
pharmacogenomics patient case exploring a particular
treatment through PharmGKB, identifying key points to
counsel patients and to discuss the pharmacogenomics of
the treatment with health care providers (Table 3).
Students also shared their perception about genetic
testing and personalized medicine (N561 out of 76) from
the Team Activity 4 (Debate). To assess how the debate
influenced their opinions on personalized medicine, three
questions were asked about their position prior to the
random assignment to the “for” or “against” groups; their
position during the debate; and their position after it. A
flowchart showing the change in their positions is depicted in Figures 1A and 1B. It is noteworthy to observe
the evolution of the 20 undecided students before and
after the activity. By the end of the debate, the personal
position of nine of these students seemed to be influenced
by the team to which they were randomly assigned (“for”
or “against”). However, seven students who initially were
undecided and assigned to the “against” teams, were still
undecided by the end of the debate. Six students who
had a personal position at the beginning of the activity
changed to undecided by the end of the experience. Students acknowledged the fact that the points of view during
the debate were assigned, and not their own.
It is noteworthy to mention some of the students’
opinions about the personalized medicine from the debate. Despite their awareness of the Genetic Information
Nondiscrimination Act (GINA), some students in the

RESULTS
Seventy-six students were enrolled in the Biopharmaceutics and Pharmacogenomics course during 2016.
Quizzes and a final examination were scheduled in the
course to assess their learning of the pharmacogenomics
material. Table 2 contains the percentage of questions
answered correctly for each category of questions based
on Bloom’s taxonomy for the pharmacogenomics section
of the course. Most of the students (80% to 85%) were
able to satisfactorily answer high-level rated questions.
All students passed the course with 50 receiving a grade of
A and 26 receiving a B.
Students had the opportunity to provide feedback
anonymously on the learning and utility of the four team
activities offered in the pharmacogenomic section of the
course (Table 3). Seventy-three out of the 76 students in
957
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Table 3. Student Perception on Active Learning Activities During the Pharmacogenomics Section of the Course (N573 out of
77 students)
Participant Response, No. (%)
VU
SU
N
NU DK NA
Do you consider the incorporation of the former active learning activities useful
for your career development and practice as PharmD?
How did each of the following team activities help you to better understand
pharmacogenomics and which one would you consider to be more useful in
your future as a pharmacist?
1: Bioinformatics
2: Personal case on pharmacokinetics-pharmacodynamics and pharmacogenomics
3: Genetic counseling
4: Personalized medicine and genetic sequencing debate

40 (55) 27 (37)

28 (38)
40 (55)
33 (45)
26 (36)

31
29
22
29

1 (1)

(42) 9 (12)
(39) 2 (3)
(30) 15 (20)
(40) 12 (16)

1 (1) 2 (3) 1 (1)

0
0
1 (1)
1 (1)

4 (5) 1 (1)
1 (1) 1 (1)
0
1 (1)
3 (4) 1 (1)

Abbreviations: VU5very useful, SU5somewhat useful, N5neither useful nor useless, NU5not useful, DK5 don’t know if this activity would be
useful for my future as pharmacist, NA5not answered (students answered other questions but left this section blank)

“against” team were concerned about negative consequences of knowing their own genetic information, such
as psychological impact on themselves and on their families after discovering that they could be at risk of potentially developing a disease, or having a mutation that was
correlated with no cure or poor prognosis, and the lifetime
implications.
The debate about personalized medicine brought
several benefits without the need of facing the risks related to students’ genetic sequencing. These benefits
include: students prepared themselves according to different scenarios and other ways of thinking, empathizing
and drawing conclusions; students felt the environment
was safe, since they were not sharing their own point
of view, but what was randomly assigned; standards 1,
3 and 4 (knowledge, improving communication, cultural
sensitivity, empathy and self-awareness) of Center for the
Advancement of Pharmacy Education (CAPE)6 were
addressed. The purpose of this fourth team activity was
to help students be better prepared for potential questions
from patients,13 such as the interpretation and meaning of
genetic testing14, direct to consumer testing, or patients’
expectations regarding scientific information. Daly reported that all of these proposals should be part of the
pharmacist training.15
At the end of the course, 73 students completed a survey assessing their confidence level in discussing pharmacogenomics concepts with health care providers and
patients in comparison to the confidence level that they
had at the beginning of the course (Figure 2). At the
beginning of the course, 86% of students considered
themselves as “unconfident,” “somewhat unconfident”
or “neither confident nor unconfident” to discuss pharmacogenomics subjects with another health care provider or
patient. At the end of the course, students reported a higher

level of confidence regarding different topics in pharmacogenomics, as well as the role of the pharmacist in this
area, with 91% saying they were confident or somewhat
confident ( p,.001). This analysis was performed comparing numbers of students who were unconfident, somewhat unconfident or did not know prior to the course with
numbers of confident and somewhat confident after the
course.
Lastly, to determine how much information learned
during the P1 year was retained in future courses, an unannounced survey on basic concepts of pharmacogenomics was given to the class when they moved to the second
year of the program. Sixty-five out of the 76 students
answered the survey. Table 4 provides the questions asked
and percentage of questions answered correctly. Most of
the students (77% to 100%) answered all the questions
correctly.
Moreover, graded pharmacogenomics questions
were also asked during the examinations in different P2
SBT courses, namely in SBT pulmonology and cardiology modules. These questions were more complex and
included therapeutic aspects not covered during the firstyear course. Nine out of the 10 questions were answered
correctly by 87% to 100% of the class of 76 students,
while the remaining question was only answered correctly by 38% of the class (not shown).

DISCUSSION
The World Health Organization (WHO) declared
that “health care providers, including pharmacists,
should be better prepared for clinical decision making
by having adequate knowledge about the medicines
for which the patient should be tested.” 16 Pharmacists
are being recognized and acknowledged as leaders in
pharmacogenomics.17
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American Journal of Pharmaceutical Education 2018; 82 (8) Article 6345.

Figure 1. Students’ Perceptions about Personalized Medicine and Genetic Sequencing from Team Activity 4 and Change of
Thinking. Students who were randomly assigned to “for” (1A) and “against” (1B) personalized medicine were asked for their
perception before, during and after the debate. Numbers describe the number of students who were “for” (F), “against” (A), or
“undecided” (U).

testing or educating patients.20,21 Some studies report that
between 10% and 13% of physicians who participated in the
study felt confident with their knowledge.20,22 There is evidence that supports a deep commitment made by pharmacy
educators to provide pharmacogenomics education among
all health sciences disciplines. Pharmacists are expected to
advise clinicians on matters related to implementation of
pharmacogenomics in patient care,23 and to ensure the use
of pharmacogenomics testing when appropriate for medication therapy.8 Furthermore, some pharmacists are also involved in developing prescribing guidelines such as those

Currently, a growing number of pharmacy students
understands the significance of pharmacogenomics for
their future practice. Lee and colleagues surveyed 2,500
pharmacy students and found that 65% of students
acknowledge the importance of pharmacogenomics.18
Moen and Lamba reported that 90% of pharmacy students
at the University of Minnesota recognized the importance
of pharmacogenomics in improving patients care.19
This data contrast studies in which physicians and other
health care providers have expressed a lack of confidence
or awareness in discussing pharmacogenomic information,
959
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have some components of pharmacogenomics in their curriculum.27 In 2010, that number grew to 69 out of 75
(92%).28 However, 40% of these schools offer 10 or fewer
didactic hours in pharmacogenomics,28 and in some situations, pharmacogenomics is offered only as an elective.
This course is taught during the P1 spring semester,
as part of a four-credit course called Biopharmaceutics
and Pharmacogenomics. Although there are some challenges in offering the course at an early stage of the education of pharmacy students, such as limited knowledge
about pharmacology, the instructor adapted the clinical
scenarios to only include drugs that were mentioned previously in other courses to facilitate the discussions.
There are also some perceived advantages in offering
the course during the first year: students have recently
learned about biopharmaceutics, pharmacokinetics, biotechnology, and biochemical pharmacology, and they
could apply those concepts without difficulty into the
pharmacogenomics section of the course. New pharmacogenomics learning and retention is incorporated and
reinforced in the integrative curriculum further in the second and third year, in the System Based Therapeutic
(SBT) courses. The pharmacogenomics learning in these
SBT courses involves the discussion of particular scenarios, applying and reinforcing the learned concepts as suggested by previous work.29 Furthermore, this P1 course
includes ethical, legal, social and economic implications,
as well as metabolomics, epigenetics and bioinformatics,
covering some of the suggested additional pharmacist
competencies27,28 that were reported as “deficient” in
some schools in the 2010 study.28

Figure 2. Student Self-Ratings of Overall Confidence and
Ability to Discuss Pharmacogenomics with Patients and
Health Care Providers. The questions asked were: what was
your confidence level about talking and discussing pharmacogenomics aspects with another health care provider or
a patient prior the course? and what is your confidence level
now after the course?
(***p,.001, Chi-square analysis, comparing unconfident,
somewhat unconfident and did not know prior to the course
with confident and somewhat confident after the course)

from the Clinical Pharmacogenetics Implementation Consortium (CPIC),15 as well as in the application of pharmacogenomics principles in practice.24 But this is an ongoing
effort because there are still pharmacists who have expressed
their lack of confidence in this matter.8,23,25,26
Pharmacogenomic education in PharmD programs
has grown rapidly. In 2005, only 32 out of 41 (78%) pharmacy schools that answered a survey described that they

Table 4. Measurement of Retention of Basic Pharmacogenomics Information 6 Months After P1 Pharmacogenomics Course
(N565 out of 76 students enrolled as P2)
Correct N (%)

Incorrect N (%)

Did not Answer

If a patient is an ultra-rapid metabolizer for a specific enzyme,
a medication metabolized by that enzyme will _____.

65 (100)

0

0

If a patient is a poor metabolizer for a specific enzyme,
a medication metabolized by that enzyme will _____.

65 (100)

0

0

If a patient is a poor metabolizer for a specific enzyme, the
patient is at risk of ______when taking a medication
metabolized by that enzyme.

58 (89)

7 (11)

0

If a patient is an ultra-rapid metabolizer for a specific enzyme,
the patient is at risk of ______when taking a medication
metabolized by that enzyme.

57 (89)

7 (11)

1

In which type of patient will a pro-drug not be effective?

50 (77)

15 (23)

0

In which type of patient will a pro-drug have risks of toxicity?

50 (77)

15 (23)

0
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Pharmacy schools are incorporating various educational approaches and strategies to teach pharmacogenomics. Weitzel and colleagues listed the different
factors that affect educational approaches, such as class
size and type of curriculum.30 Educational approaches
include didactic lectures,31 clinical exercises and online
resources,32 personal genomic sequencing,33 laboratory
exercises34 and bionformatics,35 flipping content,36 shortanswer problem solving,31 medical literature review,31
experiential activities,37 and medical evidence review,
among others. Some pharmacy schools have tried implementing students’ personal genetic sequencing,33 but this
approach could be controversial,38 and risks failing the
four pillars of genetic counseling (autonomy, confidentiality, beneficence, and justice).39
In this study, students were exposed to different topics
such as patient stratification based on genetic background
and involving predicting responders and non-responders,
or those with higher or lower risks of developing an adverse
effect, discussion of ethical issues and barriers to implementation of genetic testing such as electronic health
record or GINA.8,17,30 Group activities were offered in
addition to lectures. All group activities were well received
by the students, and were found useful for their learning.
Some of the concerns expressed by students against
personalized medicine are not unusual and have already
been expressed by a group of licensed pharmacists in
Canada.40 Additional studies with medical students in
the US and in the UK indicate that they also share the
same concerns.41
Students who participated in this study reported an
increased level of confidence with respect to their knowledge base. As mentioned in the introduction, previous
studies have shown that pharmacists were not aware of
the pharmacogenomics information in FDA labeling,40
which was one of the reasons for incorporating a team
activity involving FDA and CPIC recommendations42 as
part of the course design.
A potential limitation of these assessment methods
could be offering the retrospective pre- and post-survey
simultaneously at the end of the course. Although the
students could retrospectively reflect on their level of
knowledge, their answer could have been different if the
question was asked directly at the beginning of the course.
However, the advantage of the approach used in this study
was that student confidentiality was maintained, and, at
the same time, to match retrospective pre- and postanswers for each student. Another limitation of this study
could be associated with the lack of student response to
retention questions, since they were not linked to a grade.
The ultimate goal when designing this course was not
only to better prepare pharmacy students to explain and

interpret test results, but also to prepare them to help
patients, explain the meaning of specific genetic backgrounds, and educate them in the area of pharmacogenetics, as previously reported and suggested.43

CONCLUSION
The implementation of a new course of Pharmacogenomics with a series of active learning activities (genetic
disease, CPIC/pharmacogenomics guideline, genetic counseling, and a debate) was effective. Students found these
activities useful, and reported an increased level of confidence, awareness and knowledge to address pharmacogenomics cases with patients or with other healthcare
providers.
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